Logo image of CKPT

CHECKPOINT THERAPEUTICS INC (CKPT) Stock Fundamental Analysis

NASDAQ:CKPT - Nasdaq - US1628282063 - Common Stock

2.845  -0.15 (-5.17%)

Fundamental Rating

1

Overall CKPT gets a fundamental rating of 1 out of 10. We evaluated CKPT against 572 industry peers in the Biotechnology industry. CKPT may be in some trouble as it scores bad on both profitability and health. CKPT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CKPT has reported negative net income.
CKPT had a negative operating cash flow in the past year.
In the past 5 years CKPT always reported negative net income.
CKPT had a negative operating cash flow in each of the past 5 years.
CKPT Yearly Net Income VS EBIT VS OCF VS FCFCKPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

CKPT has a worse Return On Assets (-897.24%) than 98.76% of its industry peers.
Industry RankSector Rank
ROA -897.24%
ROE N/A
ROIC N/A
ROA(3y)-512.31%
ROA(5y)-336.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CKPT Yearly ROA, ROE, ROICCKPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CKPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CKPT Yearly Profit, Operating, Gross MarginsCKPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10K -20K -30K -40K -50K

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, CKPT has more shares outstanding
CKPT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CKPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CKPT Yearly Shares OutstandingCKPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
CKPT Yearly Total Debt VS Total AssetsCKPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

CKPT has an Altman-Z score of -114.23. This is a bad value and indicates that CKPT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -114.23, CKPT is doing worse than 97.70% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -114.23
ROIC/WACCN/A
WACCN/A
CKPT Yearly LT Debt VS Equity VS FCFCKPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 0.29 indicates that CKPT may have some problems paying its short term obligations.
CKPT has a worse Current ratio (0.29) than 95.58% of its industry peers.
A Quick Ratio of 0.29 indicates that CKPT may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.29, CKPT is doing worse than 94.87% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.29
Quick Ratio 0.29
CKPT Yearly Current Assets VS Current LiabilitesCKPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 59.29% over the past year.
Looking at the last year, CKPT shows a very negative growth in Revenue. The Revenue has decreased by -72.35% in the last year.
Measured over the past years, CKPT shows a very negative growth in Revenue. The Revenue has been decreasing by -50.63% on average per year.
EPS 1Y (TTM)59.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.69%
Revenue 1Y (TTM)-72.35%
Revenue growth 3Y-54.17%
Revenue growth 5Y-50.63%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 37.91% on average over the next years. This is a very strong growth
CKPT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 1728.87% yearly.
EPS Next Y73.05%
EPS Next 2Y37.91%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-80.57%
Revenue Next 2Y1728.87%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CKPT Yearly Revenue VS EstimatesCKPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
CKPT Yearly EPS VS EstimatesCKPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CKPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CKPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CKPT Price Earnings VS Forward Price EarningsCKPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CKPT Per share dataCKPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as CKPT's earnings are expected to grow with 37.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.91%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CKPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHECKPOINT THERAPEUTICS INC

NASDAQ:CKPT (1/22/2025, 10:34:01 AM)

2.845

-0.15 (-5.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners13.27%
Inst Owner Change1.14%
Ins Owners7.32%
Ins Owner Change33.29%
Market Cap138.92M
Analysts84.44
Price Target13.77 (384.01%)
Short Float %19.75%
Short Ratio5.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.8%
Min EPS beat(2)-53.74%
Max EPS beat(2)42.14%
EPS beat(4)1
Avg EPS beat(4)-32.11%
Min EPS beat(4)-98.49%
Max EPS beat(4)42.14%
EPS beat(8)3
Avg EPS beat(8)-18.94%
EPS beat(12)5
Avg EPS beat(12)-25.75%
EPS beat(16)6
Avg EPS beat(16)-25.97%
Revenue beat(2)1
Avg Revenue beat(2)29.66%
Min Revenue beat(2)-100%
Max Revenue beat(2)159.33%
Revenue beat(4)1
Avg Revenue beat(4)-28.63%
Min Revenue beat(4)-100%
Max Revenue beat(4)159.33%
Revenue beat(8)5
Avg Revenue beat(8)94.59%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-20.59%
PT rev (3m)-20.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)40.45%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-98.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-30.09%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2955.77
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.84
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0
BVpS-0.26
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -897.24%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-512.31%
ROA(5y)-336.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.29
Quick Ratio 0.29
Altman-Z -114.23
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.69%
EPS Next Y73.05%
EPS Next 2Y37.91%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-72.35%
Revenue growth 3Y-54.17%
Revenue growth 5Y-50.63%
Sales Q2Q%-100%
Revenue Next Year-80.57%
Revenue Next 2Y1728.87%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.55%
OCF growth 3YN/A
OCF growth 5YN/A